Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Calithera Biosci Com (CALA)

Calithera Biosci Com (CALA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 122
  • Shares Outstanding, K 4,872
  • Annual Sales, $ 9,750 K
  • Annual Income, $ -39,650 K
  • 60-Month Beta -0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CALA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -7.20
  • Most Recent Earnings N/A on 11/14/22
  • Latest Earnings Date 01/01/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0200 +25.50%
on 04/17/24
0.0500 -49.80%
on 04/15/24
+0.0051 (+25.50%)
since 03/15/24
3-Month
0.0200 +25.50%
on 04/17/24
0.1200 -79.08%
on 03/05/24
-0.0062 (-19.81%)
since 01/18/24
52-Week
0.0100 +151.00%
on 05/04/23
0.4999 -94.98%
on 06/29/23
-0.0269 (-51.73%)
since 04/18/23

Most Recent Stories

More News
Calithera: Q3 Earnings Snapshot

Calithera: Q3 Earnings Snapshot

CALA : 0.0251 (-37.25%)
KalVista (KALV) Stock Continues to Decline: Here's Why

The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.

INFI : 0.0080 (-50.00%)
CALA : 0.0251 (-37.25%)
KALV : 11.53 (+0.26%)
PHIO : 0.6378 (-1.73%)
Spectrum (SPPI) Down as FDA Panel Votes Against NSCLC Drug

The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.

SPPI : 1.0300 (unch)
INFI : 0.0080 (-50.00%)
CALA : 0.0251 (-37.25%)
PHIO : 0.6378 (-1.73%)
Pacira's (PCRX) Label Expansion Study on Exparel Meets Goal

Pacira's (PCRX) phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for bunionectomy meets primary and secondary endpoints.

INFI : 0.0080 (-50.00%)
PCRX : 26.17 (+0.27%)
CALA : 0.0251 (-37.25%)
ASRT : 0.7600 (+0.80%)
Calithera Biosciences (CALA) Q2 2022 Earnings Call Transcript

CALA earnings call for the period ending June 30, 2022.

CALA : 0.0251 (-37.25%)
Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology...

CALA : 0.0251 (-37.25%)
Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- --...

CALA : 0.0251 (-37.25%)
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory NRF2 (NFE2L2)-Mutated Squamous Non-Small Cell Lung Cancer

-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06,...

CALA : 0.0251 (-37.25%)
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB (ABC) Diffuse Large B-Cell Lymphoma

-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes -- Study will evaluate SYK inhibitor...

CALA : 0.0251 (-37.25%)
Calithera Biosciences Announces 1-for-20 Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology...

CALA : 0.0251 (-37.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.0251
2nd Resistance Point 0.0251
1st Resistance Point 0.0251
Last Price 0.0251
1st Support Level 0.0251
2nd Support Level 0.0251
3rd Support Level 0.0251

See More

52-Week High 0.4999
Fibonacci 61.8% 0.3128
Fibonacci 50% 0.2550
Fibonacci 38.2% 0.1971
Last Price 0.0251
52-Week Low 0.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar